WARSAW, Ind., Oct. 28, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced the FDA approval of its 3P™ Pediatric Plating Platform™ Small-Mini System, the second of several systems in the 3P family. This represents the company’s 6th FDA approval in 2025.
The 3P Small-Mini System is a versatile plate and screw solution featuring variable-angle locking implants designed specifically for pediatric orthopedic surgeons. It supports a wide range of trauma and deformity surgeries with procedure-specific and utility plates in sizes 2.0mm, 2.4mm, 2.7mm, and 3.5mm. Featuring specialized instruments, streamlined tray layouts, and color-coding for enhanced surgical flow, the system aims to optimize operating room efficiency. As the second release in the 3P Pediatric Plating Platform, it follows the highly successful 3P Hip System.
OrthoPediatrics President of Trauma, Deformity Correction and OPSB, Joe Hauser commented, “This milestone represents another significant step forward in the 3P product development journey. Our engineering and surgeon design teams continue to demonstrate exceptional work in advancing the next 3P system following the successful launch of 3P Hip. This innovative platform is redefining how pediatric surgeons treat their patients, addressing a significant unmet medical need, and we are excited to move toward a limited market release in early 2026.”
CEO, David Bailey echoed those comments, saying “We remain focused on delivering a comprehensive portfolio of innovative orthopedic solutions to expand our support to more pediatric patients. This is the 6th FDA approval for the company in 2025, and was received ahead of our expectations, thanks to the dedication and excellence of our R&D team. I’m incredibly proud of their work and look forward to continuing to develop not only the 3P platform but our larger portfolio with even more groundbreaking products in the near future.”
About OrthoPediatrics Corp.
Founded in 2006, OrthoPediatrics is an orthopedic company focused exclusively on advancing the field of pediatric orthopedics. As such, it has developed the most comprehensive product offering to the pediatric orthopedic market to improve the lives of children with orthopedic conditions. OrthoPediatrics currently markets over 80 products that serve three of the largest categories within the pediatric orthopedic market. This product offering spans trauma and deformity, scoliosis, and sports medicine/other procedures. OrthoPediatrics’ global sales organization is focused exclusively on pediatric orthopedics and distributes its products in the United States and over 70 countries outside the United States. For more information, please visit www.orthopediatrics.com. For more information about the OrthoPediatrics Specialty Bracing portfolio, please visit www.opsb.com.
Investor Contact
Philip Trip Taylor
Gilmartin Group
This email address is being protected from spambots. You need JavaScript enabled to view it.
415-937- 5406

| Last Trade: | US$16.91 |
| Daily Change: | -0.05 -0.29 |
| Daily Volume: | 133,541 |
| Market Cap: | US$423.930M |
October 28, 2025 October 09, 2025 September 05, 2025 August 25, 2025 August 05, 2025 | |

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load